Needham analyst Michael Matson has reiterated their bullish stance on ESTA stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson has given his Buy rating due to a combination of factors that highlight the promising outlook for Establishment Labs Holdings. The company’s recent investor day showcased positive feedback from key opinion leaders in the field of plastic surgery, particularly regarding their breast implants and procedures. These experts anticipate that Establishment Labs will secure a substantial portion of the U.S. market in the coming years.
Additionally, the management’s reaffirmation of their 2025 guidance and the expectation of exceeding consensus for the second quarter U.S. revenue further bolster confidence in the company’s growth trajectory. Despite potential global economic challenges, Establishment Labs is not experiencing a slowdown in international markets. This combination of strong market potential, positive expert endorsements, and solid financial guidance makes the stock an attractive investment opportunity.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $62.00 price target.